Cabaletta Bio Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $15.23
- Today's High:
- $16.78
- Open Price:
- $15.23
- 52W Low:
- $0.59
- 52W High:
- $13.44
- Prev. Close:
- $15.23
- Volume:
- 1501196
Company Statistics
- Market Cap.:
- $473.94 million
- Book Value:
- 2.924
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -33.45%
- Return on Equity TTM:
- -56.34%
Company Profile
Cabaletta Bio Inc had its IPO on 2019-10-25 under the ticker symbol CABA.
The company operates in the Healthcare sector and Biotechnology industry. Cabaletta Bio Inc has a staff strength of 66 employees.
Stock update
Shares of Cabaletta Bio Inc opened at $15.23 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $15.23 - $16.78, and closed at $16.49.
This is a +8.27% increase from the previous day's closing price.
A total volume of 1,501,196 shares were traded at the close of the day’s session.
In the last one week, shares of Cabaletta Bio Inc have increased by +23.8%.
Cabaletta Bio Inc's Key Ratios
Cabaletta Bio Inc has a market cap of $473.94 million, indicating a price to book ratio of 2.3109 and a price to sales ratio of 0.
In the last 12-months Cabaletta Bio Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-56772000. The EBITDA ratio measures Cabaletta Bio Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cabaletta Bio Inc’s operating margin was 0% while its return on assets stood at -33.45% with a return of equity of -56.34%.
In Q1, Cabaletta Bio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Cabaletta Bio Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cabaletta Bio Inc’s profitability.
Cabaletta Bio Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.2211. Its price to sales ratio in the trailing 12-months stood at 0.
Cabaletta Bio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $103.45 million
- Total Liabilities
- $9.31 million
- Operating Cash Flow
- $24.62 million
- Capital Expenditure
- $380000
- Dividend Payout Ratio
- 0%
Cabaletta Bio Inc ended 2024 with $103.45 million in total assets and $0 in total liabilities. Its intangible assets were valued at $103.45 million while shareholder equity stood at $91.65 million.
Cabaletta Bio Inc ended 2024 with $0 in deferred long-term liabilities, $9.31 million in other current liabilities, in common stock, $-181416000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $93.85 million and cash and short-term investments were $93.85 million. The company’s total short-term debt was $2,181,000 while long-term debt stood at $0.
Cabaletta Bio Inc’s total current assets stands at $95.73 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $0 compared to accounts payable of $3.96 million and inventory worth $0.
In 2024, Cabaletta Bio Inc's operating cash flow was $24.62 million while its capital expenditure stood at $380000.
Comparatively, Cabaletta Bio Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $16.49
- 52-Week High
- $13.44
- 52-Week Low
- $0.59
- Analyst Target Price
- $14.17
Cabaletta Bio Inc stock is currently trading at $16.49 per share. It touched a 52-week high of $13.44 and a 52-week low of $13.44. Analysts tracking the stock have a 12-month average target price of $14.17.
Its 50-day moving average was $13.13 and 200-day moving average was $10.35 The short ratio stood at 11.15 indicating a short percent outstanding of 0%.
Around 1098.1% of the company’s stock are held by insiders while 7635.8% are held by institutions.
Frequently Asked Questions About Cabaletta Bio Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children’s Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.